CytomX Therapeutics Inc — Cash Flow (NASDAQ:CTMX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities 5.26 M-119.03 M-110.79 M-56.03 M-86.23 M-75.59 M -75.59 M Cash from investing activities -18.72 M22.49 M98.26 M-150.67 M99.7 M-59.74 M -59.74 M Cash from financing activities 16.89 M110.21 M648 K30.23 M7.52 M110.45 M 110.45 M Free cash flow 2.95 M-120.64 M-112.53 M-56.88 M-86.54 M-75.81 M -75.81 M

News

Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?

3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts - TipRanks.com

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

CytomX Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CTMX) 2026-03-17

CytomX launches $250M public offering to fund drug development

Micron and Intel among market cap stock movers on Monday

CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) (CTMX)

Micron, Intel among market cap stock movers on Monday

CytomX Therapeutics Inc earnings missed by $0.24, revenue fell short of estimates

Oppenheimer raises CytomX stock price target on trial data

CytomX March 2026 slides: Varseta-M efficacy exceeds standard of care

Earnings call transcript: CytomX Therapeutics Q4 2025 highlights clinical progress